A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. (REDUCE)

Novartis

Status and phase

Completed

Phase 3

Conditions

Liver Transplant

Treatments

Drug: TAC + MMF + corticosteroids

Drug: Minimisation of TAC

Study type

Interventional

Funder types

Industry

Identifiers

NCT02040584

CRAD001HES01

2013-001191-38 (EudraCT Number)

Details and patient eligibility

About

Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC (rTAC) may offer improved kidney function compared with standard therapy with TAC-MMF.

Full description

A multicentre, randomized, open-label, controlled, exploratory clinical trial with 12-months (52 weeks) of follow-up.

Enrollment

217 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Screening Visit - Inclusion Criteria

Recipients age 18 or over receiving a first liver transplant from a cadaver donor.
Patients diagnosed with HCC must meet the Milan radiological criteria at the time of transplant (1 nodule ≤5 cm in diameter, or 2-3 nodules, all <3 cm in diameter) - at time of patient's inclusion on the waiting list.

Anh: done.
Patients who have signed the informed consent to participate in the study.
Patients who by medical criteria are capable of complying with the study regimen.

Screening Visit - Exclusion Criteria

Recipients who have received multiple transplants of solid organs or pancreatic islet cells.
Patients who have previously received an organ or tissue transplant.
Patients with a combined liver-kidney transplant.
Recipients of lobes or segments of liver from a live donor.
A history of malignancy of any organ system in the previous 3 years according to local protocols (regardless of signs of local recurrence or metastasis), other than non-metastasising basal cell carcinoma or squamous cell carcinoma (epidermoid carcinoma) of the skin, or HCC.
Patients with known hypersensitivity to the drugs used in the study or others of their class, or to any of their excipients.
Recipients of ABO-incompatible transplants.
Patients who test positive for HIV.
Recipients of organs from donors who tested positive for the hepatitis B surface antigen or HIV seropositive.
Patients with any medical or surgical condition that in the opinion of the investigator may significantly alter the absorption, distribution, metabolism or excretion of the study medication.
Women of childbearing potential (i.e. women who are not postmenopausal with amenorrhoea of more than 1 year or surgically sterile) who are planning to become pregnant, are pregnant and/or breastfeeding, or who do not wish to use effective contraception, e.g. hormonal contraceptives (implantation, patches, oral) and double-barrier methods (any double combination of: IUD, male or female condoms with spermicidal gel, diaphragm, contraceptive sponge, cervical cap).
Patients who are taking part in another clinical trial.

Randomisation Visit - Inclusion Criteria

Functioning allograft at the time of randomisation. A functioning allograft is defined as:
1. levels of AST, ALT and total bilirubin ≤ 4 times the upper limit of normal, and
2. levels of alkaline phosphatase and GGT ≤ 5 times the upper limit of normal.
Glomerular filtrate ≥30 mL/min/1.73 m2 (calculated using the MDRD-4 equation).

Randomisation Visit - Exclusion Criteria

Patients with proteinuria ≥1.0 g/24 hrs confirmed in the urine sample (protein/creatinine ratio) that cannot be explained by immediate post-operative causes.
Patients with severe hypercholesterolaemia (≥350 mg/dL; ≥9 mmol/L) or severe hypertriglyceridaemia (≥750 mg/dL; ≥8.5 mmol/L).
Patients with a platelet count ≤50,000/mm3.
Patients with an absolute neutrophil count ≤1,000/mm3 or WBC count ≤2,000/mm3.
Patients who cannot take oral medication.
Patients with clinically significant systemic infection who require active use of intravenous antibiotics.
Patients who are in intensive care units and require vital support measures such as mechanical ventilation, dialysis, or vasoactive drugs.
Patients who have required renal replacement therapy in the 7 days prior to randomisation.
Patients who have had an episode of acute rejection and have required antibody therapy or who have had more than one episode of corticosteroid-sensitive acute rejection.